FOXO4-DRI — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

FOXO4-DRI

Also known as: FOXO4-D-Retro-Inverso, FOXO4-p53 interfering peptide, cell-permeable FOXO4-p53 interfering peptide, FOXO4 DRI, retro-inverso senolytic peptide

Senolytic peptide (D-retro-inverso peptide / cell-penetrating peptide)

Research chemicalLast updated: October 19, 2026Based on 17 peer-reviewed studies

What it is

FOXO4-DRI is a senolytic peptide being studied in animals for its ability to selectively eliminate aged, dysfunctional cells that accumulate with age and drive chronic inflammation. It works by triggering a form of cell death specifically in these senescent cells. Not FDA-approved; no human trials; evidence comes from animal studies.

The scientific side

FOXO4-DRI is an all-D-amino-acid retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53. Under normal senescent-cell physiology, FOXO4 binds p53 in nuclear bodies and sequesters it, preventing p53 from inducing apoptosis and thereby maintaining senescent cell viability. FOXO4-DRI competitively interferes with this FOXO4–p53 interaction; structural NMR studies show that the disordered FOXO4-DRI binds the disordered p53 transactivation domain and forms a transiently folded complex, with p53 phosphorylation enhancing binding affinity. By displacing FOXO4, the peptide promotes nuclear exclusion of phosphorylated p53 (PMID 39994346; PMID 41625068), which subsequently activates pro-apoptotic effectors including BAX and cleaved caspase-3 via the p53/BCL-2/Caspase-3 pathway, selectively inducing apoptosis in senescent cells while leaving non-senescent (healthy) cells largely unaffected (PMID 28340347; PMID 42024235).

Class: Senolytic peptide (D-retro-inverso peptide / cell-penetrating peptide)

Administration & storage

Administration
Intraperitoneal injection — used in neonatal rat BPD model (PMID: 37874230)Injection in aged and progeroid mice for vascular aging studies — route not further specified beyond 'injection' (PMID: 41625068)In vitro direct cell treatment — keloid organ cultures and fibroblasts (PMID: 39994346)In vitro direct cell treatment — expanded chondrocytes (PMID: 33996787)In vitro direct cell treatment — senescent Leydig cells (PMID: 31959736)
Storage
No abstract in the reviewed literature explicitly describes storage conditions for FOXO4-DRI.
Cautions
FOXO4-DRI has not been clinically validated in humans; all efficacy and safety data are from preclinical (animal and in vitro) models.,Senolytic clearance of senescent pulmonary endothelial cells with FOXO4-DRI worsened pulmonary hemodynamics in animal models of pulmonary hypertension, indicating potential context-dependent harm.,Long-term toxicology, pharmacokinetics, and delivery studies for FOXO4-DRI have not been reported in the reviewed literature; clinical translation requires such data.,Disruption of p53-dependent tumor surveillance is a theoretical risk of FOXO4-p53 axis interference that requires explicit assessment.,Sterile technique is essential for any injectable peptide preparation to minimize infection risk.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification